Jonathan Sevilla-Cazes1, Brian S Finkleman2, Jinbo Chen3, Colleen M Brensinger3, Andrew E Epstein4, Michael B Streiff5, Stephen E Kimmel6. 1. Perelman School of Medicine at the University of Pennsylvania, Philadelphia. 2. Perelman School of Medicine at the University of Pennsylvania, Philadelphia; Center for Clinical Epidemiology and Biostatistics, Philadelphia, Penn; Center for Therapeutic Effectiveness Research, Philadelphia, Penn. 3. Perelman School of Medicine at the University of Pennsylvania, Philadelphia; Center for Clinical Epidemiology and Biostatistics, Philadelphia, Penn. 4. Perelman School of Medicine at the University of Pennsylvania, Philadelphia; Corporal Michael J. Crescenz Veterans Affairs Medical Center, Philadelphia, Penn. 5. Johns Hopkins University School of Medicine, Baltimore, Md. 6. Perelman School of Medicine at the University of Pennsylvania, Philadelphia; Center for Clinical Epidemiology and Biostatistics, Philadelphia, Penn; Center for Therapeutic Effectiveness Research, Philadelphia, Penn. Electronic address: stevek@mail.med.upenn.edu.
Abstract
BACKGROUND: The prevention of thromboembolism events remains challenging in cases of poor medication adherence. Unfortunately, clinical prediction of future adherence has been suboptimal. The objective of this study was to examine the correlation between 2 measures of real-time, self-reported adherence and anticoagulation control. METHODS: The IN-RANGE2 cohort recruited patients initiating warfarin therapy in 3 urban anticoagulation clinics. At each study visit, participants reported adherence using a 100-point visual analogue scale (VAS, marking percentage of pills taken since prior visit on a linear scale) and 7-day recall of pill-taking behavior. Anticoagulation control was measured by between-visit percent time in international normalized ratio range (BVTR), dichotomized at the cohort median. The longitudinal association between adherence and anticoagulation control was estimated using generalized estimating equations, controlling for clinical and demographic characteristics, prior BVTR, and warfarin dose changes. RESULTS: Among 598 participants with 3204 (median 4) visits, the median BVTR was 36.8% (interquartile range 0%-73.9%). Participants reported ≤80% adherence in 182 visits (5.7%) and missed pills in the past 7 days in 377 visits (11.8%). Multivariable regression analysis found poorer anticoagulation control (BVTR <36.8%) in those with a VAS ≤80% (odds ratio 1.89; 95% confidence interval, 1.12-3.18; P = .02) and self-reported change in adherence since last visit (odds ratio 1.55; 95% confidence interval, 1.20-2.01; P = .001). CONCLUSION: Self-reported VAS medication adherence at a clinic visit and changes in reported adherence since the last visit are independently associated with BVTR. Clinicians may gain additional insight into patients' medication adherence by incorporating this information into patient management.
BACKGROUND: The prevention of thromboembolism events remains challenging in cases of poor medication adherence. Unfortunately, clinical prediction of future adherence has been suboptimal. The objective of this study was to examine the correlation between 2 measures of real-time, self-reported adherence and anticoagulation control. METHODS: The IN-RANGE2 cohort recruited patients initiating warfarin therapy in 3 urban anticoagulation clinics. At each study visit, participants reported adherence using a 100-point visual analogue scale (VAS, marking percentage of pills taken since prior visit on a linear scale) and 7-day recall of pill-taking behavior. Anticoagulation control was measured by between-visit percent time in international normalized ratio range (BVTR), dichotomized at the cohort median. The longitudinal association between adherence and anticoagulation control was estimated using generalized estimating equations, controlling for clinical and demographic characteristics, prior BVTR, and warfarin dose changes. RESULTS: Among 598 participants with 3204 (median 4) visits, the median BVTR was 36.8% (interquartile range 0%-73.9%). Participants reported ≤80% adherence in 182 visits (5.7%) and missed pills in the past 7 days in 377 visits (11.8%). Multivariable regression analysis found poorer anticoagulation control (BVTR <36.8%) in those with a VAS ≤80% (odds ratio 1.89; 95% confidence interval, 1.12-3.18; P = .02) and self-reported change in adherence since last visit (odds ratio 1.55; 95% confidence interval, 1.20-2.01; P = .001). CONCLUSION: Self-reported VAS medication adherence at a clinic visit and changes in reported adherence since the last visit are independently associated with BVTR. Clinicians may gain additional insight into patients' medication adherence by incorporating this information into patient management.
Authors: Stephen E Kimmel; Zhen Chen; Maureen Price; Catherine S Parker; Joshua P Metlay; Jason D Christie; Colleen M Brensinger; Craig W Newcomb; Frederick F Samaha; Robert Gross Journal: Arch Intern Med Date: 2007-02-12
Authors: Alec B Platt; A Russell Localio; Colleen M Brensinger; Dean G Cruess; Jason D Christie; Robert Gross; Catherine S Parker; Maureen Price; Joshua P Metlay; Abigail Cohen; Craig W Newcomb; Brian L Strom; Mitchell S Laskin; Stephen E Kimmel Journal: Chest Date: 2009-11-10 Impact factor: 9.410
Authors: David P Nau; Douglas T Steinke; L Keoki Williams; Roger Austin; Jennifer Elston Lafata; George Divine; Manel Pladevall Journal: Ann Pharmacother Date: 2007-10-09 Impact factor: 3.154
Authors: Sudeep Karve; Mario A Cleves; Mark Helm; Teresa J Hudson; Donna S West; Bradley C Martin Journal: Curr Med Res Opin Date: 2009-09 Impact factor: 2.580
Authors: Catherine S Parker; Zhen Chen; Maureen Price; Robert Gross; Joshua P Metlay; Jason D Christie; Colleen M Brensinger; Craig W Newcomb; Frederick F Samaha; Stephen E Kimmel Journal: J Gen Intern Med Date: 2007-06-22 Impact factor: 5.128
Authors: Christopher Ll Morgan; Phil McEwan; Andrzej Tukiendorf; Paul A Robinson; Andreas Clemens; Jonathan M Plumb Journal: Thromb Res Date: 2008-12-04 Impact factor: 3.944
Authors: Holly Guy; Vicki Laskier; Mark Fisher; W Richey Neuman; Iwona Bucior; Steven Deitelzweig; Alexander T Cohen Journal: Pharmacoeconomics Date: 2019-05 Impact factor: 4.981
Authors: Victoria Speed; Vivian Auyeung; Jignesh P Patel; Derek Cooper; Stephen Miller; Lara N Roberts; Raj K Patel; Roopen Arya Journal: Res Pract Thromb Haemost Date: 2021-11-21